OncoMed begins second Phase 1b clinical trial for OMP-54F28 with sorafenib OncoMed Pharmaceuticals (OMED) announced that it has started a multi-center Phase 1b clinical trial of OMP-54F28 with sorafenib in hepatocellular cancer, or HCC. OMP-54F28 is a first-in-class Wnt-pathway-targeting decoy receptor and is part of OncoMed's collaboration with Bayer Pharma AG (BAYRY). This is the second of three Phase 1b trials for OMP-54F28 to begin patient enrollment; earlier this year OncoMed initiated a Phase 1b of OMP-54F28 with nab-paclitaxel and gemcitabine in pancreatic cancer. The Phase 1b clinical trial is a dose-escalation study of OMP-54F28 in combination with sorafenib in patients with first-line locally advanced or metastatic HCC. Primary objectives of the trial are to evaluate safety of this combination regimen and determine a recommended Phase 2 dose for OMP-54F28 in combination with sorafenib. Key secondary and exploratory objectives include evaluation of the pharmacokinetics and pharmacodynamics of OMP-54F28, as well as the efficacy of this combination. Tumor tissue from patients will be used to explore predictive biomarker hypotheses related to the efficacy of OMP-54F28.
Bayer says not looking to sell crop chemicals business, Reuters reports Bayer (BAYRY) says its Bayer CropScience unit is an "integral part" of the company and that the division is not for sale, Reuters reports. Bayer's comments come after Monsanto (MON) executives said that it is in internal discussions about tie-ups in the industry. Reference Link